Steps Biosciences and RDGVRP Launch Dedicated Formulations R&D Centre in Bengaluru

Steps Biosciences and RDGVRP have opened a dedicated formulations R&D centre in Bengaluru, signalling a structural investment in complex drug delivery and sterile injectables at a time when Indian CDMOs face increasing scrutiny over development-stage process controls and ICH Q10-aligned quality systems.

The facility is designed to support differentiated dosage forms alongside sterile injectable development, two categories that carry elevated regulatory expectations under 21 CFR Part 211 and corresponding Schedule M requirements. Integrating specialised workflows from the outset positions the centre to address sterility assurance and process validation requirements before programmes reach commercial-scale transfer.

For QA directors and regulatory affairs leads evaluating development partners, the infrastructure build-out matters at the point of technology transfer planning. Facilities that embed scientific infrastructure for complex delivery systems early reduce the risk of late-stage process gaps that typically surface during pre-approval inspections or process performance qualification runs.

The Bengaluru location places the centre within a recognised life sciences cluster, providing access to analytical talent and regulatory consulting networks that support submission-ready development packages across ICH regions.

How the centre's quality management framework maps to ICH Q10 principles, and whether it operates under a site-specific pharmaceutical quality system from day one, will be a practical checkpoint for any sponsor evaluating the partnership for regulated-market programmes.

Source: Indian Pharma Post via Media4Growth, 3 June 2026.